Table 3.
Summary of cardiovascular trials with nicotinic acid derivatives or CETP inhibitors showing that most patients included in these trials had normal HDL‐C levels
| Study compound | Study name | Baseline HDL‐C (mg/dL)a |
|---|---|---|
| Nicotinic acid | ||
| Extended‐release niacin | AIM‐HIGH | 34.5 ± 5.6 |
| Extended‐release niacin + laropiprant | HPS‐2 THRIVE | 43.9 ± 11.2 |
| CETP inhibitors | ||
| Torcetrapib | ILLUMINATE | 48.6 ± 12.0 |
| Dalcetrapib | DAL‐OUTCOMES | 42.5 ± 11.7 |
| Evacetrapib | ACCELERATE | 45.3 ± 11.7 |
| Anacetrapib | REVEAL | 40 ± 10 |
CETP, cholesteryl ester transfer protein; HDL‐C, high‐density lipoprotein‐cholesterol.
a
Values in the active group.